Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Nanogam, is an Immunoglobulin presented as a sterile solution for Intravenous use. It provides passive immunity for patients with primary or secondary immunodeficiency diseases. GNH USA supplies Nanogam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Nanogam is used in the management of immune‑deficient conditions where IgG replacement is required. - Primary immunodeficiency diseases: supplies pooled IgG to reduce the frequency and severity of infections. - Secondary immunodeficiency (e.g., chemotherapy, HIV): provides passive antibodies that support immune function during treatment. - Prevention of infections in immunocompromised patients: lowers the risk of bacterial and viral infections by enhancing humoral immunity.

Nanogam may cause a range of adverse reactions, most of which are related to the infusion process or the immunoglobulin content.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever and chills: transient rise in body temperature and shivering. - Nausea: occasional upset stomach during administration. - Fatigue: feeling of tiredness post‑infusion. - Infusion‑related reactions: flushing, erythema, or mild hypotension. - Muscle aches: soreness in limbs after treatment.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: blood clots that may affect veins or arteries. - Renal dysfunction: impaired kidney function, especially with high‑dose regimens. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe thrombocytopenia: markedly low platelet count increasing bleeding risk.

Before initiating Nanogam therapy, clinicians should evaluate patient history and monitor for potential complications. - Assess baseline IgG levels: determine need for replacement therapy. - Monitor for infusion reactions: observe vital signs during and after administration. - Adjust infusion rate in renal impairment: slower rates reduce renal stress. - Avoid in patients with known IgA deficiency and anti‑IgA antibodies: risk of severe anaphylaxis. - Use caution during pregnancy: safety data are limited, weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid): - Live vaccines: concurrent use may diminish vaccine efficacy and increase infection risk. - Other immunoglobulin products: combined therapy can lead to IgG overload and increased adverse events.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment infection susceptibility, requiring closer monitoring. - Anticoagulants: immunoglobulin can affect coagulation parameters, potentially altering bleeding risk. - ACE inhibitors: may increase incidence of hypotensive episodes during infusion. - Immunosuppressants: combined effect on immune system warrants regular assessment of infection markers.